News

Our Healthcare News

Molecular Partners Announces Agreement with Swiss Government, Securing Rights to Purchase Doses of First Anti-COVID-19 DARPin® Program

· Swiss Government will pay a reservation fee for the right to purchase up to 3.2 million doses of anti-COVID-19 DARPin® candidate, MP0420, for both…  

Aug 12 2020

Servier completes the acquisition of Symphogen

Symphogen becomes the antibody center of excellence within Servier strengthening the Group’s pipeline

Paris (France), June 4, 2020 – Servier, an independent…  

Jun 04 2020

Molecular Partners Confirms Ultra-Potent Inhibition of SARS-CoV-2 Live Virus by Anti-COVID-19 DARPin® Candidates

- DARPin® antiviral candidates demonstrate low picomolar potency in live virus assay
- Candidate construction complete; two candidates ready for preclinical development & manufacturing 

May 08 2020

Molecular Partners Initiates Anti-COVID-19 Therapeutic Program Leveraging Multi-Target Binding of DARPin® Proteins to Neutralize SARS-CoV-2 Virus

·  First trispecific anti-COVID-19 therapeutic program: targets three parts of the viral “spike” protein with one drug candidate for broad inhibition of infection and mitigation…  

Apr 21 2020

Servier signed a definitive agreement to acquire Symphogen, a leading antibody discovery company, to boost its antibody capabilities and leverage its R&D pipeline

- Servier strengthens its R&D pipeline by acquiring Symphogen’s antibody pipeline and next-generation antibody technologies.
- Symphogen becomes the antibody center of excellence within…  

Apr 03 2020

Molecular Partners Announces Newly Nominated Board Members for Upcoming Annual Meeting

Sandip Kapadia, Michael Vasconcelles and Vito J. Palombella nominated for election to the Board of Directors of Molecular Partners at the upcoming Annual General…  

Feb 19 2020

Molecular Partners Announces First Patient Dosed in Phase 1 Trial of MP0310, a Novel Tumor-Localized Immunotherapy

Zurich-Schlieren, SWITZERLAND—Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies*, today announced that…  

Oct 03 2019

Allergan and Molecular Partners Announce Acceptance of U.S. FDA Biologics License Application and Validation of EMA Marketing Authorisation for Abicipar pegol in Patients with Neovascular (Wet) Age-related Macular Degeneration

Filing includes data from two Phase 3 trials which evaluated the safety and efficacy of Abicipar quarterly dosing regimen

Approvals in the United States and…  

Sep 09 2019

Molecular Partners' Strategic Partner Allergan Announced Today that EMA has Validated the Marketing Authorisation Application for Abicipar

ZURICH-SCHLIEREN, Switzerland—Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies*, today announced that…  

Aug 06 2019